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Measuring Overall Heterogeneity in Meta-Analyses:
Application to CSF Biomarker Studies in Alzheimer’s Disease
Chengjie Xiong1, Feng Gao1, Yan Yan1,2, Jingqin Luo1, YunJu Sung1, & Gang Shi1
Washington University in St. Louis
The interpretations of statistical inferences from meta-analyses depend on the degree of heterogeneity in
the meta-analyses. Several new indices of heterogeneity in meta-analyses are proposed, and assessed the
variation/difference of these indices through a large simulation study. The proposed methods are applied
to biomakers of Alzheimer’s disease.
Keywords: Alzheimer’s disease, heterogeneity, meta-analysis, standard errors, uncertainty interval.

This showed a significant divergence between
expert recommendations and the summaries of
the trials.
Ineffective treatments were being
recommended, and highly effective treatments
were not. As a result, lives that could have been
saved were lost, and resources were wasted.
Systematic reviews can be very useful medical
decision-making
tools
by
objectively
summarizing large amounts of information,
identifying gaps in medical research and
evidence, and identifying beneficial or harmful
interventions. Clinicians can use systematic
reviews to guide their patient care. Consumers
and patients can use systematic reviews to help
them make health care decisions. Policymakers
can use systematic reviews to help them make
decisions about the types of health care to
provide.
Systematic reviews can provide
convincing and reliable evidence relevant to
many aspects of medical and biological research
and health care (Egger & Smith, 1997),
especially when the results of individual studies
they include show clinically important effects of
comparable magnitude. Such reviews aim to
comprehensively identify and assess all studies
relevant to a given scientific question, and metaanalysis has been the major statistical
methodology for the quantitative synthesis of
study results. Many methods for meta-analysis
are available, and the most popularly applied in
the medical research focus on the optimum
combination of published summary statistics in
some form of weighted averages (DerSimonian

Introduction
Medical practitioners and their patients make
decisions within the context of a rapidly
changing body of scientific evidence on
medicine and health care system that influence
the availability, accessibility, and cost of
diagnostic tests and therapies (Sackett &
Haynes, 1995).
Timely, useful evidence from the
biomedical literature should be an integral
component of clinical and medical decision
making. The importance of basing medical
practice more firmly on the results of existing
scientific evidence through systematic reviews
was starkly demonstrated by a paper in the early
1990s (Antman, Kupelnick, Mosteller, &
Chalmers, 1992), which compared the results of
meta-analyses of trials of treatments for people
who have suffered a heart attack as the trials
were published with the recommendations of
experts published in review articles and
textbooks over the same time period.
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studies in a meta-analysis is small, and excessive
power to detect clinically insignificant
heterogeneity when there are too many studies
(Higgins & Thompson, 2002).
Addressing statistical heterogeneity of
studies is one of the most fundamental aspects of
many systematic reviews. The interpretative
aspects of statistical inferences from a metaanalysis depend on the degree of heterogeneity
of the studies used in the meta-analysis. Because
the heterogeneity may determine the extent to
which the conclusions of a meta-analysis can be
generalized, it is important to quantify the extent
of heterogeneity among a collection of studies.
Realizing the potential limitations of a statistical
test to characterize the degree of heterogeneity
in a meta-analysis, Higgins and Thompson
(2002) proposed a new measure of the extent of
heterogeneity in a meta-analysis that overcomes
the shortcomings of existing measures.
Their focus is on the impact of
heterogeneity on the results of a meta-analysis
and therefore, on the degree to which conclusion
might be generalized to situations outside those
investigated in the studies at hand. Their
measure is easily interpretable by nonstatisticians as the proportion of variation that
was explained by the difference among studies.
Further, the measure does not intrinsically
depend on the number of studies or the type of
outcome data, therefore offering the possibility
that statistical heterogeneity can be compared
across different meta-analyses with differing
number of studies and types of outcome data.
In this article, several new indices are
proposed that measure the heterogeneity from
studies used in a meta-analysis. The proposed
methodology can be regarded as a generalization
of the index of heterogeneity proposed by
Higgins and Thompson (2002). The difference
among the proposed measures of heterogeneity
are examined, along with the variation of each
proposed measure when a large number of
simulated meta-analyses are conducted. The
proposed methodology is demonstrated by
presenting an example to study possible
cerebrospinal fluid (CSF) biomakers that could
be used to identify subjects with high risk of
developing Alzheimer’s disease (AD) when they
are still cognitively normal.

& Laird, 1986; Egger, Smith, & Phillips, 1997;
& Whitehead & Whitehead, 1991).
Usually, each study is given a weight
according to the precision of its results on
summary statistics. Studies with good precisions
are weighted more heavily than studies with
greater uncertainty. The variance for the overall
estimate of the parameter under study in metaanalyses is in general from two different
sources, one is associated with the individual
studies (i.e., the within-study variance), and the
other is associated with the possible difference
between different studies (i.e., between-study
variance). When the between-study variance is
assumed to be 0, each study is simply weighted
according to its own variance. This approach
characterizes a fixed effects model which is
exemplified by the Mantel-Haenszel method
(Mantel & Haenszel, 1959) or the Peto method
(Yusuf, Peto, Lewis, Collins, & Sleight, 1985).
When the between-study variance is not
zero, methods which incorporate a betweenstudy component of variation for the overall
effect under estimation are based on random
effects models (Laird, & Mosteller, 1990). The
between-study variance represents the excessive
variation in observed individual study effects
over that expected from the imprecision of
results within each study. Fixed effects and
random effects model for general continuous
outcome and specific survival outcomes have
also been described in Hedges and Olkin (1985),
Earle & Wells (2000), Parmar, Torri, & Stewart,
(1998) and Srinivasan & Zhou (1993).
When individual studies used in a metaanalysis have very differing results, however,
the results from systematic reviews may be less
convincing and reliable. In an attempt to
establish whether study results are consistent,
reports on meta-analysis commonly present a
statistical test of heterogeneity among studies
used in a meta-analysis. This test seeks to
determine whether there are genuine differences
underlying the results of the studies, or whether
the variation in these results is compatible with
chance alone (i.e., homogeneity). A common
statistical test used for this purpose is the
Cochran’s Chi-squared test or the Q-test
(Whitehead & Whitehead, 1991; Cochran,
1954). It has been widely realized, however, that
this test has poor power when the number of
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Indices of overall heterogeneity in a metaanalysis

σˆ θ2ˆ =
r

Assume that a total of k studies are used
in a meta-analysis to address a scientific

A test of homogeneity of the θ i ’s is given by

be the estimate from the i-th study and σˆ i2 be
the associated estimated variance which is
assumed to be known. Let wi = 1 / σˆ i2 denote
the precision of the estimate. In a classic fixed
effect meta-analysis, θ i ’s are assumed identical

k

Q =  wi (θˆi − θˆ) 2 ,
i =1

which has a Chi-squared distribution with k-1
degrees of freedom under the assumption of
homogeneity within the fixed effects model.
Within the framework of the random effect
model, a method of moment estimate to τ 2 can
also be obtained as

and a summary estimate, θˆ , is computed to the
common parameter as a weighted average of the
study specific estimates, using the precisions as
weights:

θˆ =


i =1
k

 wi

k

.

w

i

i =1

1
i

i =1

I2 =

A random effects meta-analysis can be
conceptualized by incorporating a random effect
to
account
for
the
between-study
2
variation, N (0,τ ) , into the estimated studyspecific parameters, in addition to the withinstudy random variation, N (0, σ i2 ) . The
summary estimate to the mean parameter across

1
−1

( wi + τ 2 )

i =1
k

w

i

τ2
,
τ 2 +σ 2

where σ 2 is the shared within-study variance
among individual studies, or when the studies
have differing within-study variations, the
typical within-study variance in the term of
Higgins and Thompson (2002). This intuitive
definition of the heterogeneity has several major
advantages as compared to the standard
statistical test based on Q. First, the definition of
I 2 depends on the study specific estimates and
is therefore based on the impact rather than the
extent of heterogeneity in a meta-analysis.
Second, the measure does not inherently depend
on the number of studies in the meta-analysis.
Third, the measure is not specific to a particular
metric of treatment effect and therefore can be
applied similarly irrespective of the type of
outcome
variables
(e.g.,
dichotomous,
continuous, and survival). Fourth, the measure is

the distribution of the studies, θˆr , has exactly
the same form as above, but with weights
replaced by

wˆ i* =

w

(1)

Higgins and Thompson (2002) proposed a
simple index to quantify the overall
heterogeneity among studies in a meta-analysis:

.

w

−

.

2
i

i =1

The variance of the summary estimate is given
by
k

k

i

i =1

σˆ θ2ˆ =

Q − (k − 1)

τˆ 2 =

w θˆ
i

w

.

*
i

i =1

question as represented by parameter θ . Let θˆi

k

1
k

.

The estimated variance of the summary estimate
is now given by
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easy to compute and has a very appealing
interpretation as the percentage of the total
variation across studies due to heterogeneity.
The estimation of overall heterogeneity
among studies in a meta-analysis requires the
estimate to both the between-study variation and
the typical within-study variance. For the latter,
Higgins and Thompson (2002) used the
following estimator

2

IT =

σ̂ HT 2 =

i =1

k

k

( wi ) −  w
2

i =1

I HT

.

2
i

k

i =1

Q − (k − 1)
τˆ 2
= 2
=
2
Q
τˆ + σˆ HT

σ̂ S 2 =

(2)

IS =

Higgins and Thompson’s (2002) intuitive
conceptualization
of
the
measure
of
heterogeneity is followed, and several new
measures of heterogeneity are proposed. First, as
pointed out by Takkouche et al. (Takkouche,
Cadarso Surez, & Spiegelman, 1999), the typical
within-study variance σ 2 can also be estimated
by taking the reciprocal of the arithmetic mean
weights:

k

2

w

=

(3)

j =1

 k

 wj 


 j =1 

2

1

w
j =1

k

j

,

τˆ 2
τˆ 2 + σˆ S 2

Q − (k − 1)
2
 k
 . (4)
k

  w j  −  w2j 


k

j =1
1  j =1 
Q − k +1+ 
k
j =1 w j
k  wj
j =1

These proposed indices of heterogeneity are set
to 0 if Q ≤ (k − 1) . By Schwartz’s inequality
(Nobel & Daniel, 1977),

.

k

k w

.
2
j

which, again along with the method of moment
estimator τˆ 2 in Equation (1), results in another
index of overall heterogeneity
2

σ̂ T =

k

Another straightforward estimator to the typical
within-study variance σ 2 can be obtained by
simply averaging the within-study variances
from all studies:

This, along with the method of moment
estimator τˆ 2 , results in the index of overall
heterogeneity
2

Q − (k − 1)
Q +1−

k

(k − 1) wi

τˆ 2
=
τˆ 2 + σˆ T 2

j

j =1

2

k
 k

  w j  ≤ k  w 2j


j =1
 j =1 

Combine this with the method of moment
estimator τˆ 2 in Equation (1) to obtain another
index of overall heterogeneity

and
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 k
2
k =  wj
 j =1


normal distribution. Therefore, if ln(Q) is
assumed a normal distribution, by equating

2

k
k
1 
1
≤  wj 
.

wj 
j =1
j =1 w j

Z with

It then follows that

ln(Q) − ln(k − 1)
, one can approximate
SE (ln(Q))

the standard error of ln(Q) by

I S2 ≤ I T2

SE (ln(Q)) =

and

2Q − 2k − 3

.

This then results in a 95% uncertainty interval to

2
I HT
≤ I T2 .

2

I T as [ I T21 , I T22 ] , where

Notice that for all these indices of overall
heterogeneity, although they have different
denominators, they share the same numerator,
which is Q − (k − 1) . If all within-study
variations
are
exactly
the
same,
2
2
2
then I HT = I T = I S .
Notice
that
the
denominator of all these proposed overall
measures of heterogeneity is the unconditional
variance of the estimated effect from a typical
study in the meta-analysis, which contains
additive components due to the within-study
variance (i.e., from between-patient variation
within a study) and the between-study variation
(i.e., heterogeneity).

IT 12 =

exp(ln(Q) − 1.96 SE (ln(Q))) − (k − 1)
k

exp(ln(Q) − 1.96 SE (ln(Q))) + 1 −

k  w2j
j =1

 k

  wj 
 j =1 

and

IT 22 =

exp(ln(Q) + 1.96SE(ln(Q))) − (k −1)
k

exp(ln(Q) +1.96SE(ln(Q))) + 1 −

Variation of the proposed overall measures of
heterogeneity
Higgins and Thompson (2002) proposed
several ways of estimating the variation

[ I S21 , I S22 ] , where

associated with I HT . They recommended the
use of an uncertainty interval based on the
statistical significance of Q due to the
appropriate nominal coverage in their simulation
studies. Because the other measures of overall
heterogeneity we proposed here also depend on
Q, we use similar test-based methods (Miettinen,
1976) to estimate the variability associated with
2

I T and I S as well. More specifically, let
Z = 2Q − 2k − 3 .
Based on a well known normal approximation to
Chi-squared distributions (Abramowitz &
Stegun, 1965), when the degrees of freedom are
large, Z follows approximately a standard
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.

kw

2
j

j =1

2

 k

  wj 
 j =1 

Similarly, a 95% uncertainty interval to I S

2

2

ln(Q) − ln(k − 1)

2

is

2
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I S 12 =

e x p (ln ( Q ) − 1 .9 6 S E (ln ( Q ))) − ( k − 1)
2
k
 k


   w j  −  w 2j 
k

j =1

1   j = 1
e x p (ln ( Q ) − 1 .9 6 S E (ln ( Q ))) − k + 1 + 
k
j =1 w j
k wj
j =1

and

I S 22 =

ex p (ln ( Q ) + 1 .9 6 S E (ln ( Q ))) − ( k − 1)
.
2
k
 k


   w j  −  w 2j 
k

j =1

1   j = 1
ex p (ln ( Q ) + 1 .9 6 S E (ln ( Q ))) − k + 1 + 
k
j =1 w j
k wj
j =1

analysis is k = 3 s + 1 for s = 2, 4, 8, and 12.
In each simulated meta-analysis, three different
within-study variances are assumed such that the
precision wi is either 0.5+v, or 0.5+2v, or
0.5+3v for a range of v. More specifically,
among k = 3s + 1 studies in the meta-analysis,
s+1 studies have within-study precision 0.5+v,
and the other 2s studies are equally distributed
with study precision 0.5+2v and 0.5+3v. A
random effect model was used to generate the
study-specific estimates such that the betweenstudy component was generated from the normal
distribution N (5,4) through
a
linear
transformation of the SAS Institute function
RANNOR (SAS, 1999). One thousand
independent simulated meta-analyses were
performed such that study specific estimates
from each individual simulation were
independently generated. Table 1 presents the
mean and the associated standard error for the
three
proposed
measures
of
overall
heterogeneity over 1000 simulated metaanalyses as a function of k and v (notice that
parameter v here indicates a measure of
difference among the study precisions).

Comparison of the proposed overall indices of
heterogeneity
Although mathematically, I S2 ≤ I T2 ,
2
I HT
≤ I T2 , it is important to understand how

different these measures are when they are used
to measure the overall heterogeneity in a metaanalysis and how much variation each index has
when a large number of meta-analyses are
conducted. Given the fact that when all studies
have exactly the same degree of within-study
variation, i.e., when all wi ’s are the same, these
measures are identical to each other, we
anticipate that these measures will be close to
each other when the difference among withinstudy variations is relatively small.
A simulation study is performed to look
at the performance of our proposed measures of
overall and study-specific heterogeneity. We
first examined the distributions and consistency
of three different measures of overall
2
heterogeneity, I S2 , I T2 , and I HT
, over a large
number of simulated meta-analyses. Assume
that the between-study variance is τ 2 = 4 . The
number of studies in each simulated meta-
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the disease’s later stages. Thus, whether CSF
β -amyloid 42 is decreased among subjects of
normal aging who are ApoE4 positive as
compared to these who are ApoE4 negative is
studied.
Although many publications have
compared CSF β -amyloid 42 level between
subjects with AD and these with normal aging
(Fagan, Roe, Xiong, et al., 2007, Sunderland,
Linker, Mirza et al., 2003), very few have
actually reported CSF β -amyloid 42 as a
function of ApoE4 status among subjects who
were still cognitively normal. As a matter of
fact, our comprehensive MEDLINE search
identified a total of 6 published studies on CSF
β -amyloid 42 during the period of 1990 to 2007
which actually reported summary statistics as a
function of ApoE4 status for subjects who were
not demented (Prince, Zetterberg, Andreasen, et
al. 2004, Sunderland, Mirza, Putnam, et al.,
2004, Jensen, Schroder, Blomberg et al., 1999,
Andreasen, Hesse, Davidson et al., 1999,
Tapiola, Pirtitla, Mehta, et al., 2000,
Riemenschneider, Schmolke, Lautenschalager,
et al, 2000). The summary statistics reported
from these six published studies are presented in
Table 2 (summary statistics from study by
Prince, Zetterberg, Andreasen, et al., 2004) was
obtained through eye-balling because only a
graphical presentation on summary statistics was
available in the publication).
Based on the proposed methodology and
a random effect model, the pooled estimate to
the mean difference of CSF β -amyloid 42
between subjects of normal aging who are
ApoE4 positive and subjects who are ApoE4
negative is -31.69 pg/mL, and an asymptotic
95% confidence interval estimate to the mean
difference of CSF β -amyloid 42 is from 128.93 pg/mL to 65.56 pg/mL. The observed
significance level for the observed mean
difference is 0.407. The measures of overall
heterogeneity from this meta-analysis are
2
estimated as
I HT
= 0.56, I T2 = 0.66, and

From the simulated meta-analyses, it is
clear that three different measures of overall
heterogeneity are very consistent. In fact, under
the assumption that the three measures of
heterogeneity are estimating the same
underlying trait of heterogeneity, the intraclass
correlation coefficient (ICC) (Shrout & Fleiss,
1979) was computed over 1,000 simulated metaanalyses for each choice of k and v. All these
computed ICCs were at least 0.99, indicating
extremely high consistency among these
measures.
Application to biomarker studies in Alzheimer ’s
disease
An application to the proposed overall
measures of heterogeneity is presented to study
possible biomakers that can be used to identify
subjects with high risk of developing
Alzheimer’s disease (AD) when they are still
cognitively normal. Researchers in Alzheimer’s
disease have identified Apolipoprotein E4
(ApoE4) alleles as a crucial genetic risk factor of
AD (Myers, Schaefer, Wilson, et al., 1996).
Although the pathological hallmarks of AD are
the neurofibrillary tangles and the senile plaques
in the brain (Braak & Braak, 1991, McKell,
Price, Miller, Grant, Xiong, Berg, & Morris,
2004), the diagnosis of AD in living patients is
still largely a clinical judgment based on careful
neurological
and/or
neuropsychological
examinations combined with results from other
clinical tests.
Therefore, the search for biomarkers
that could be used to diagnose AD from normal
aging has been one of the primary research
activities in AD. In several publications (Fagan,
Roe, Xiong, et al., 2007, Sunderland, Linker,
Mirza, et al., 2003), subjects with AD have been
found to have decreased level of cerebrospinal
fluid (CSF) β -amyloid 42 as compared to
subjects with normal aging. Because AD is a
progressive neurodegenerative disorder that
leads to the death of brain cells that cannot be
replaced once lost, it is important to assess the
potential of these biomarkers to identify subjects
that are at high risk of AD while they are still
cognitively normal. The importance of such
biomarkers is further highlighted by the fact that
no pharmaceutical treatments are effective for

I S2 = 0.20, respectively, indicating from low to
moderate degree of heterogeneity among studies
used in the meta-analysis (Higgins, Thompson,
Deeks et al., 2003). Further, an estimated 95%
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Table 1. Three Measures of Overall Heterogeneity from 1000 Simulated Meta-analyses
(k = the number of studies in meta-analyses,
(0.5+v, 0.5+2v, 0.5+3v) = the three within-study precisions)
2

2

2

k

v

Mean I HT (SE) (%)

Mean I T (SE) (%)

Mean I S (SE) (%)

7

0

39.29 (0.85)

39.29 (0.85)

39.29 (0.85)

7

0.5

73.83 (0.58)

74.06 (0.57)

72.68 (0.58)

7

1.0

83.73 (0.45)

83.97 (0.45)

82.46 (0.46)

7

1.5

88.48 (0.31)

88.70 (0.30)

87.28 (0.32)

7

2.0

90.17 (0.29)

90.38 (0.29)

89.04 (0.31)

13

0

43.04 (0.66)

43.04 (0.66)

43.04 (0.66)

13

0.5

79.33 (0.34)

79.43 (0.34)

78.14 (0.35)

13

1.0

87.27 (0.19)

87.37 (0.19)

85.99 (0.21)

13

1.5

90.80 (0.15)

90.89 (0.15)

89.65 (0.16)

13

2.0

92.56 (0.14)

92.64 (0.14)

91.53 (0.15)

25

0.0

46.16 (0.50)

46.16 (0.50)

46.16 (0.50)

25

0.5

81.25 (0.18)

81.30 (0.18)

80.05 (0.19)

25

1.0

88.62 (0.13)

88.66 (0.12)

87.40 (0.14)

25

1.5

91.89 90.08)

91.93 (0.08)

90.81 (0.09)

25

2.0

93.69 (0.07)

93.73 (0.07)

92.76 (0.08)

37

0.0

47.41 (0.39)

47.41 (0.39)

47.41 (0.39)

37

0.5

81.88 (0.15)

91.91 (0.15)

80.69 (0.16)

37

1.0

89.22 (0.09)

89.25 (0.09)

88.03 (0.10)

37

1.5

92.16 (0.07)

92.18 (0.07)

91.10 (0.08)

37

2.0

93.94 (0.05)

93.96 (0.05)

93.03 (0.06)
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Table 2. Reported Summary Statistics from Six Studies on CSF β -amyloid 42 (in pg/mL) as a
Function of ApoE4 Genotype
(Author = the first author of the study, Year = the year of the publication,
n + = the sample size of subjects who are ApoE4 positive,

n − = the sample size of subjects who are ApoE4 negative,

Mean (SD)+ = mean (standard deviation) in subjects who are ApoE4 positive,
Mean (SD)- = mean (standard deviation) in subjects who are ApoE4 negative)
Author

Year

n+ / n−

Mean (SD)+

Mean (SD)-

Andreasen N
Jensen M
Tapiola T
Riemenschneide M
Sunderland T
Prince JA

1999
1999
2000
2000
2004
2004

8/13
4/20
13/25
3/15
57/85
32/86

1641.00 (587.00)
365.72 (85.79)
500.00 (211.00)
914.67 (11.37)
389.00 (108.00)
697.00 (228.00)

1702.00 (339.00)
329.60 (139.97)
522.00 (136.00)
860.00 (194.00)
443.00 (109.00)
840.00 (185.00)

2
uncertainty interval for I HT
is from 0.00 to
0.82, an estimated 95% uncertainty interval for
I T2 is from 0.00 to 0.88, and an estimated

account of heterogeneity (i.e., random effect
models) or ignore the heterogeneity (i.e., fixed
effect models) further highlights the importance
to assess the heterogeneity in meta-analyses.

uncertainty interval for I S2 is from 0.00 to 0.48
(the uncertainty intervals were truncated to 0
when the left limits were negative as similarly
recommended in Higgins & Thompson, 2002).
If the heterogeneity is ignored in the
meta-analysis, i.e., the between-study variance
is
treated
as
0
(therefore
τ2
2
2
2
I HT = I T = I S = 0), then a fixed effect model
would be used for the meta-analysis. The
estimated overall mean difference of CSF β -

Conclusion
We proposed several new indices that measure
the overall heterogeneity among studies used in
a meta-analysis. By estimating the typical
within-study precisions, we developed indices
that measure the degree of heterogeneity among
studies by their impact to the overall conclusion
of the meta-analysis. The proposed methodology
can be regarded as a generalization of the index
of heterogeneity proposed by Higgins and
Thompson (2004). We assessed the variation
associated with each proposed index of
heterogeneity through a large simulation study
of 1000 meta-analyses for a range of relevant
parameters. We also examined the difference
among the proposed overall measures of
heterogeneity when a large number of metaanalyses were conducted. We found that these
different indices provided highly consistent
results in measuring the overall heterogeneity in
meta-analyses. Finally, we demonstrated our
proposed methodology by presenting an
example to study possible biomakers that could

amyloid 42 between subjects of normal aging
who are ApoE4 positive and subjects who are
ApoE4 negative under the fixed effect model is 45.35 pg/mL. An asymptotic 95% confidence
interval estimate to the mean difference of CSF
β -amyloid 42 under the fixed effect model is
from -74.89 pg/mL to -15.82 pg/mL, suggesting
a statistically significant difference at a 5%
significance level on CSF β -amyloid 42 between
subjects of normal aging who are ApoE4
positive and subjects who are ApoE4 negative.
This discrepancy on the statistical inference
between the two approaches that either take into
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Fagan, A. M., Roe, C. M., Xiong, C., et
al. (2007). Cerebrospinal fluid tau/ β -amyloid 42
ratio as a prediction of cognitive decline in
nondemented older adults. Archives in
Neurology,64.
(doi:10.1001/archneur.64.3.noc60123).
Hardy, R. J., & Thompson, S. G. (1998).
Detecting and describing heterogeneity in metaanalysis. Statistics in Medicine, 17, 841-856.
Hedges, L. V., & Olkin, I. (1985).
Statistical methods for meta-analysis. Orlando:
Academic Press.
Higgins, J. P. T., & Thompson, S. G.
(2002). Quantifying heterogeneity in a metaanalysis. Statistics in Medicine, 21, 1539-1558.
Higgins, J. P. T., Thompson, S. G.,
Deeks, J. J., et al. (2003). Measuring
inconsistency in meta-analyses. British Medical
Journal, 327, 557-560.
Jensen, M., Schroder, J., Blomberg, M.,
et al. (1999). Cerebrospinal fluid Aβ 42 is
increased early in sporadic Alzheimer’s disease
and declines with disease progression. Ann
Neurol, 45, 504-511.
Laird, N. M., & Mosteller, F. (199).
Some statistical methods for combining
experimental results. The International Journal
of Technology Assessment in Health Care, 6, 530.
Mantel, N., Haenszel, W. (1959).
Statistical aspects of the analysis of data from
retrospective studies of disease. Journal of the
National Cancer Institute., 22, 719-748.
McKeel, D. W., Jr., Price, J. L., Miller,
J. P., Grant, E. A., Xiong, C., Berg, L., &
Morris, J. C. (2004). Neuropathologic criteria
for diagnosing Alzheimer disease in persons
with pure dementia of Alzheimer type. Journal
of
Neuropathology
and
Experimental
Neuropathology, 63(10), 1028-1037.
Miettinen, O. (1976) Estimability and
estimation in case-referent studies. American
Journal of Epidemiology, 103, 226-235.
Myers, R. H., Schaefer, E. J., Wilson, P.
W. F., et al. (1996). Apolipoprotein E ε 4
association with dementia in a population-based
study: The Framingham study. Neurology, 46,
673-677.

be used to identify subjects with high risk of
developing Alzheimer’s disease (AD) when they
are still cognitively normal. The inconsistent
statistical inferences to this real world example
based on statistical approaches with or without
taking into account of heterogeneity highlight
the crucial role heterogeneity plays in metaanalyses.
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